A recent meta-analysis has raised concerns about a potential increase in cardiovascular risk among patients treated with rosiglitazone. NPS has released a fact sheet, Rosiglitazone and cardiovascular risk, which discusses this issue.
Date published: 01 August 2007
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
